ClinicalTrials.gg
CompletedNCT02647125Updated Nov 26, 2024

A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC

A Phase 2 interventional study of Huachansu and thoracic radiation in Esophageal Squamous Cell Carcinoma, sponsored by Fudan University. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2015, registered Dec 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Esophageal Squamous Cell Carcinoma by Fudan University — 12 open to participants now, 15 under way, 2 of them phase 3. Esophageal Squamous Cell Carcinoma · Fudan University.

Enrollment
13th of 30
126 · median 104
Started
2015
with 2 others
Phase 2
18 of 37
5 open now
Registered
10th of 37
by date

Among the 37 studies in Esophageal Squamous Cell Carcinoma by Fudan University, this one is the 13th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2015, is one of 18 in phase 2, and was the 10th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

12 of the 37 studies in Esophageal Squamous Cell Carcinoma by Fudan University are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Esophageal Squamous Cell Carcinoma by Fudan University, or all of them as a file.
02

Study summary

This primary objective of the trial is to study whether the local control of Huachansu plus thoracic radiotherapy is better compared to thoracic radiotherapy alone for patients with esophageal squamous cell carcinoma. It's a phase II study, 134 patients are expected to be recruited into the trial.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Joined the study voluntarily and signed form.
  2. Age >75 or age 18-75 who are intolerant of or reject intravenous chemotherapy.
  3. Both genders.
  4. Esophageal squamous cell carcinoma confirmed by pathology.
  5. Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a,TxN1M0-1a,TxNxM1a, AJCC 6th).
  6. No radiotherapy, chemotherapy or other treatments prior to enrollment.
  7. PS 0-2,wight loss\<30% during the latest 6 months.
  8. of more than 3 months.
  9. (Hb)≥9 g/dL,WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L count (Pt) ≥100x 109/L.Hepatic function: ALAT and ASAT \< 2.5 x , \<1.5 x ULN.Renal function: creatinine \< 1.5 x ULN.
  10. No immuno-deficiency
  11. No heart diseases that need cardiac glycoside
  12. Use of an effective for adults to prevent pregnancy.

Exclusion criteria

Exclusion Criteria:

  1. Complete esophageal obstruction.
  2. Deep esophageal ulcer.
  3. Esophageal perforation.
  4. Haematemesis.
  5. After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting therapy.
  6. Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years.
  7. Pregnant or breast-feeding women or people during the birth-period who refused to take .
  8. Drug addiction,Alcoholism or AIDS.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Huachansu Arm

    Patients in this arm will receive a treatment of Huachansu combined with thoracic radiotherapy.

    Drug: Huachansu · Radiation: thoracic radiation

  • Active comparator
    Control Arm

    Patients in this arm will receive thoracic radiotherapy alone.

    Radiation: thoracic radiation

Interventions

  • Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.

  • Radiationthoracic radiation

    A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.

06

What researchers measure

Primary outcomes

  1. Local control rate

    The outcome measure will be assessed by every 3-month follow-up examinations.

    Time frame: the date of randomization until progression inside the irradiation field, up to 3 years.

Secondary outcomes

  1. overall survival

    The survival time from date of randomization to the day of death or the last follow-up.

    Time frame: the date of randomization until the death or the last follow up of the patients, up to 3 years.

  2. progress-free survival

    Measured from date of randomization until progression or death from any cause

    Time frame: the date of randomization until progression or death from any cause, up to 3 years

07

Study locations

1 site
  • Fudan Universtiy Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Sep 2022, 84 months.

Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's 84 months is above that.

Counting every sponsor, half of 174 studies reached it within 41 months; a quarter within 28 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2015
First posted
Jan 6, 2016
StartActual
Sep 2015
Primary completionActual
Sep 2022
CompletionActual
Dec 2022
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02647125
Lead sponsor
Fudan University
Responsible party
Kuai Le Zhao, MD (Professor, Fudan University) — Principal investigator
First posted
Jan 6, 2016
Start date
Sep 2015
Primary completion
Sep 2022
Completion
Dec 2022
Last update
Nov 26, 2024

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Huachansu

Start the discussion